NuCana plc: NuCana Reports First Quarter 2022 Financial Results and Provides Business Update
Initiated Randomized Phase 2 Study of NUC-3373 in Patients with Colorectal Cancer Initiated Phase 1b/2 Study of NUC-3373 in Combination with Other Agents, Including PD-1 Inhibitors, in Patients with
Source: finanznachrichten.de